Skip to content

PUFAs in Preterm Infants

Characteristics of PUFAs Composition in Preterm Infants and Its Impact on Disease Prognosis

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06045130
Acronym
PIPI
Enrollment
600
Registered
2023-09-21
Start date
2023-09-21
Completion date
2026-08-31
Last updated
2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPD - Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Necrotizing Enterocolitis, Patent Ductus Arteriosus, Periventricular Leukomalacia, Sepsis

Keywords

PUFAs

Brief summary

The research endeavors to examine the critical composition of Polyunsaturated Fatty Acids (PUFAs) in premature infants across different gestational stages and under varying disease conditions, and delineate the metabolic attributes of PUFAs in premature infants and their interplay with the onset of diseases. This study anticipates furnishing a theoretical foundation for the rationalization of PUFAs supplementation in premature infants and for informing strategies related to disease prevention and management.

Interventions

None listed

Sponsors

The First Hospital of Jilin University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Infants born between 24 and 36 weeks of gestational age who are admitted within 24 hours of birth, including both premature and full-term newborns. \-

Exclusion criteria

Infants with severe congenital developmental abnormalities, those requiring external supplementation of PUFAs in addition to standard intravenous nutrition and breastfeeding, and those with a severe prognosis indicating non-survival during their hospitalization. \-

Design outcomes

Primary

MeasureTime frameDescription
Mortality and severe complications of premature infantsbefore dischargeincidence of death,NEC,PDA,BPD,IVH,PVL and sepsis

Secondary

MeasureTime frameDescription
NECbefore dischargeBell stage II or III
PDAbefore dischargeconfirmed by echocardiography
BPDbefore dischargenasal CPAP/NIPPV or invasive ventilation requirement at 36 weeks postmenstrual age or at discharge, transfer or death if before 36 weeks
Mortalitybefore dischargedeath
PVLbefore dischargeperiventricular cysts on cranial ultrasound or magnetic resonance imaging
sepsisbefore dischargeblood culture positive
IVHbefore dischargePapile grades 3-4

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026